Description

CILOSTAHEAL 100MG

Indications

Cilostahheal 100mg is primarily indicated for the treatment of intermittent claudication in patients with peripheral arterial disease (PAD). This condition is characterized by pain and discomfort in the legs due to inadequate blood flow during physical activity. Cilostahheal is used to improve walking distance and alleviate the symptoms associated with this condition. Additionally, it may be beneficial in enhancing the quality of life for patients suffering from PAD.

Mechanism of Action

The active ingredient in Cilostahheal, cilostazol, is a phosphodiesterase type 3 (PDE3) inhibitor. By inhibiting this enzyme, cilostazol increases intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels lead to vasodilation and inhibition of platelet aggregation. The vasodilatory effect improves blood flow to the affected areas, thereby reducing the symptoms of intermittent claudication. Furthermore, cilostazol enhances exercise tolerance by improving muscle oxygenation during physical activity.

Pharmacological Properties

Cilostahheal exhibits several pharmacological properties that contribute to its therapeutic effects. It is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 2 to 4 hours. The drug undergoes extensive metabolism in the liver, primarily through cytochrome P450 enzymes, resulting in active metabolites that also contribute to its pharmacological effects. The elimination half-life of cilostazol is approximately 11 hours, allowing for once or twice daily dosing in most patients.

Contraindications

Cilostahheal is contraindicated in patients with a history of hypersensitivity to cilostazol or any of its components. It should not be used in individuals with heart failure of any severity, as it may exacerbate the condition. Additionally, patients with active bleeding disorders or those who are concurrently using other medications that may increase the risk of bleeding should avoid cilostahheal. Pregnant or breastfeeding women should also refrain from using this medication unless deemed necessary by a healthcare provider.

Side Effects

Common side effects associated with cilostazol include headache, diarrhea, dizziness, and palpitations. These side effects are generally mild to moderate in intensity and may resolve with continued use of the medication. However, more serious adverse effects, such as tachycardia, hypotension, and gastrointestinal bleeding, may occur in some patients. It is essential for patients to report any unusual or severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of Cilostahheal is typically 100mg taken orally twice daily, approximately 30 minutes before meals. It is crucial to adhere to the prescribed dosage to maximize therapeutic benefits while minimizing the risk of adverse effects. In some cases, a healthcare provider may adjust the dosage based on individual patient response and tolerability. Patients should be advised not to exceed the recommended dose, as higher doses do not necessarily confer additional benefits and may increase the risk of side effects.

Interactions

Cilostahheal may interact with various medications, potentially altering their effects or increasing the risk of adverse reactions. Notably, concurrent use of cilostazol with other antiplatelet agents, such as aspirin or clopidogrel, may increase the risk of bleeding. Additionally, medications that inhibit CYP3A4, such as certain antifungal agents and macrolide antibiotics, may increase cilostazol levels, necessitating careful monitoring. It is essential for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements.

Precautions

Patients with a history of cardiovascular disease, renal impairment, or hepatic dysfunction should use cilostahheal with caution. Regular monitoring of blood pressure and heart rate is recommended, particularly in patients with a history of cardiac issues. Additionally, patients should be advised to avoid activities that may increase the risk of injury or bleeding while taking this medication. It is important to maintain regular follow-up appointments with a healthcare provider to assess the efficacy and safety of cilostahheal therapy.

Clinical Studies

Clinical studies have demonstrated the efficacy of cilostazol in improving walking distance and reducing symptoms of intermittent claudication in patients with PAD. In a randomized controlled trial, patients treated with cilostazol showed a significant increase in treadmill walking distance compared to those receiving a placebo. Furthermore, cilostazol has been shown to improve quality of life measures in patients with PAD, making it a valuable therapeutic option in this population. Long-term studies indicate that cilostazol is generally well-tolerated and effective in managing symptoms associated with peripheral arterial disease.

Conclusion

Cilostahheal 100mg is a clinically effective medication for the management of intermittent claudication due to peripheral arterial disease. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable option for improving patient outcomes. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should engage in open communication with their healthcare providers to ensure optimal management of their condition while using cilostahheal.